BioRegenx, Inc.
BRGX
$0.008
$0.000.00%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -22.73% | -18.80% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -22.73% | -18.80% | |||
| Cost of Revenue | 20.45% | -56.70% | |||
| Gross Profit | -32.99% | 2.49% | |||
| SG&A Expenses | 655.29% | -73.94% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 177.78% | -47.95% | |||
| Operating Income | -542.90% | 68.52% | |||
| Income Before Tax | -4,559.56% | 64.30% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4,559.56% | 64.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4,559.56% | 64.30% | |||
| EBIT | -542.90% | 68.52% | |||
| EBITDA | -718.81% | 245.75% | |||
| EPS Basic | -4,625.00% | 66.67% | |||
| Normalized Basic EPS | -366.67% | 57.14% | |||
| EPS Diluted | -4,625.00% | 66.67% | |||
| Normalized Diluted EPS | -366.67% | 57.14% | |||
| Average Basic Shares Outstanding | 1.59% | 0.00% | |||
| Average Diluted Shares Outstanding | 1.59% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||